InvestSMART

Cellmid Limited (ASX: CDY) - Announcements

- Current share price for CDY : $0.056

ASX company news and announcements for Cellmid Limited (CDY) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cellmid Limited (CDY) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cellmid Limited (CDY), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cellmid Limited (CDY)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- CELLMID COMPLETES US CONSUMER STUDY 21 Aug 2017 9:17AM $0.024 $0.056 risen by 133.33%
- CELLMID SECURES PREMIUM US RETAIL CHANNEL FOR EVOLIS 3 Aug 2017 9:29AM $0.026 $0.056 risen by 115.38%
- Chinese Import Permits Received 1 Aug 2017 9:29AM $0.024 $0.056 risen by 133.33%
- Appendix 4C - quarterly 28 Jul 2017 11:05AM $0.026 $0.056 risen by 115.38%
- Nature Paper MK in Melanoma 3 Jul 2017 10:32AM $0.025 $0.056 risen by 124%
- Change of Director's Interest Notice-Halasz 5 Jun 2017 2:27PM $0.028 $0.056 risen by 100%
- Appendix 3B 15 May 2017 9:58AM $0.029 $0.056 risen by 93.10%
- Change of Director's Interest Notice-Halasz 15 May 2017 9:35AM $0.029 $0.056 risen by 93.10%
- Change of Director's Interest Notice-Halasz 12 May 2017 3:57PM $0.029 $0.056 risen by 93.10%
- Company Secretary Appointment/Resignation 27 Apr 2017 1:20PM $0.029 $0.056 risen by 93.10%
- Appendix 4C - quarterly 19 Apr 2017 11:17AM $0.029 $0.056 risen by 93.10%
- Change of Director's Interest Notice - Halasz 16 Mar 2017 11:56AM $0.030 $0.056 risen by 86.67%
- Response to ASX query on Appendix 3Y 13 Mar 2017 4:48PM $0.029 $0.056 risen by 93.10%
- CELLMIDS FGF5 INHIBITOR CLINICAL STUDY PUBLISHED 2 Mar 2017 11:44AM $0.031 $0.056 risen by 80.65%
- Cellmid to Refinance R&D Loan Facility 1 Mar 2017 2:10PM $0.032 $0.056 risen by 75%
- Appendix 4D and Half Year Accounts 28 Feb 2017 8:59AM $0.034 $0.056 risen by 64.71%
- MIDKINE ALOPECIA PATENT EUROPEAN ALLOWANCE 7 Feb 2017 9:04AM $0.032 $0.056 risen by 75%
- CELLMID'S USA MIDKINE PATENT FOR ALOPECIA ALLOWED 31 Jan 2017 10:13AM $0.028 $0.056 risen by 100%
- Appendix 4C 24 Jan 2017 9:54AM $0.027 $0.056 risen by 107.41%
- CELLMID RECEIVES AUSTRALIAN GOVT GRANT FOR MIDKINE PROGRAMME 18 Jan 2017 11:52AM $0.026 $0.056 risen by 115.38%
- Change of Director's Interest Notice - Halasz 18 Jan 2017 9:37AM $0.025 $0.056 risen by 124%
- Cellmid Updates on CxBladder License 12 Dec 2016 2:32PM $0.026 $0.056 risen by 115.38%
- Cellmid receives 831K R&D tax credit 29 Nov 2016 2:29PM $0.029 $0.056 risen by 93.10%
- Results of Annual General Meeting 21 Nov 2016 1:25PM $0.030 $0.056 risen by 86.67%
- AGM Presentation by CEO 21 Nov 2016 10:32AM $0.030 $0.056 risen by 86.67%

301 - 325 of 530 results

Page 13 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.